Clinical Ink, Inc is a leading provider of innovative eSource solutions for decentralized clinical trials. Their eSource ecosystem, which integrates Direct Data Capture (DDC) technology and electronic Clinical Outcome Assessments (eCOA), allows for the ingestion of data from multiple sources, enabling faster and higher-quality clinical trial data. With a focus on patient-centered technologies, Clinical Ink aims to simplify study startup, standardize processes, and empower patients through their eConsent, eLAS Suite, and Mobile Devices solutions.
By minimizing complexity, accelerating study build, and covering a wide range of therapeutic areas, Clinical Ink's eCOA technology sets a new standard for speed, efficiency, and accuracy in the study build process. Their commitment to recentering decentralized clinical trials and capturing data directly from the patient is evident in their comprehensive suite of solutions, which aim to facilitate lupus trials, deliver reach and efficiency through mobile devices, and benefit from easy and efficient televisit capabilities.
Generated from the website
